Participant flow

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors · Source last updated 2024-12-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Dose escalation with rebastinib 50 milligram (mg) twice daily (BID) orally (PO) in 21-day cycles in combination with carboplatin administered by intravenous (IV) infusion at area under the curve (AUC)5 at Day 1 of each 21-day cycle.

   id

   FG000

   title

   Part 1 Cohort 1 Escalation Rebastinib 50 mg + Carboplatin AUC5

2. description

   Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.

   id

   FG001

   title

   Part 1 Cohort 2 Escalation Rebastinib 100 mg + Carboplatin AUC5

3. description

   Dose escalation with rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC6 at Day 1 of each 21-day cycle.

   id

   FG002

   title

   Part 1 Cohort 3 Escalation Rebastinib 100 mg + Carboplatin AUC6

4. description

   Dose expansion in triple-negative breast cancer (TNBC) participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.

   id

   FG003

   title

   Part 2 Cohort 1 Expansion Rebastinib 50 mg + Carboplatin AUC5

5. description

   Dose expansion in TNBC participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.

   id

   FG004

   title

   Part 2 Cohort 1 Expansion Rebastinib 100 mg + Carboplatin AUC5

6. description

   Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.

   id

   FG005

   title

   Part 2 Cohort 2 Expansion Rebastinib 50 mg + Carboplatin AUC5

7. description

   Dose expansion in platinum-sensitive ovarian cancer participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.

   id

   FG006

   title

   Part 2 Cohort 2 Expansion Rebastinib 100 mg + Carboplatin AUC5

8. description

   Dose expansion in mesothelioma participants. Rebastinib 50 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.

   id

   FG007

   title

   Part 2 Cohort 3 Expansion Rebastinib 50 mg + Carboplatin AUC5

9. description

   Dose expansion in mesothelioma participants. Rebastinib 100 mg BID PO in 21-day cycles in combination with carboplatin administered by IV infusion at AUC5 at Day 1 of each 21-day cycle.

   id

   FG008

   title

   Part 2 Cohort 3 Expansion Rebastinib 100 mg + Carboplatin AUC5

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         14

      3. group Id

         FG002

         num Subjects

         5

      4. group Id

         FG003

         num Subjects

         9

      5. group Id

         FG004

         num Subjects

         2

      6. group Id

         FG005

         num Subjects

         18

      7. group Id

         FG006

         num Subjects

         2

      8. group Id

         FG007

         num Subjects

         6

      9. group Id

         FG008

         num Subjects

         11

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         12

      3. group Id

         FG002

         num Subjects

         5

      4. group Id

         FG003

         num Subjects

         9

      5. group Id

         FG004

         num Subjects

         2

      6. group Id

         FG005

         num Subjects

         18

      7. group Id

         FG006

         num Subjects

         2

      8. group Id

         FG007

         num Subjects

         6

      9. group Id

         FG008

         num Subjects

         11

      comment

      Modified Intent-to-Treat (mITT) Population includes all participants who had at least one full dose of the combined study drugs, had measurable disease at baseline, and had at least one post-baseline assessment. Participants without a post-baseline assessment who discontinued study treatment due to clinical progression, death, or a rebastinib-related AE will also be included in the mITT population.

      type

      mITT Population

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         7

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         4

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         12

      7. group Id

         FG006

         num Subjects

         0

      8. group Id

         FG007

         num Subjects

         3

      9. group Id

         FG008

         num Subjects

         3

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         7

      3. group Id

         FG002

         num Subjects

         5

      4. group Id

         FG003

         num Subjects

         5

      5. group Id

         FG004

         num Subjects

         2

      6. group Id

         FG005

         num Subjects

         6

      7. group Id

         FG006

         num Subjects

         2

      8. group Id

         FG007

         num Subjects

         3

      9. group Id

         FG008

         num Subjects

         8

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice